Answers are grounded in this paper and cite their sources.
Pre-eclampsia is a disease unique to human pregnancy, affecting approximately 5% of pregnant women. It is defined by the maternal syndrome of de novo hypertension (occurring after 20 weeks of gestation) and proteinuria. It is cured by delivery of the placenta, typically with complete clinical resolution by the third post-partum month [1]. Despite major advances in understanding its pathophysiology, its cause remains unknown. Pre-eclampsia continues to be a major cause of maternal morbidity and mortality worldwide, with eclamptic deaths estimated at 50 000 annually [2]. The fetus may be affected by this disease, with growth restriction, fetal distress and pre-term delivery being common. Maternal and perinatal complications are more likely in certain situations; when the clinical onset is before 33 weeks of gestation, when there are other medical disorders (e.g. renal disease) and in developing countries [3]. Pre-eclampsia was previously considered as a disease with no long-term sequelae [4]. This model is not supported by evidence from recent large follow-up studies. The analyses from Iceland [5], Norway [6], Jerusalem [7] and Scotland [8] (approximately 800 000 pregnancies) have demonstrated an increased risk of cardiovascular death in women with previous pre-eclampsia, particularly where pre-term delivery occurred [6,8]. Overall, the increased risk of death in these studies is approximately two-fold. However, the Norwegian study identified an up to eight-fold increase in cardiovascular death in women who had pre-eclampsia and pre-term delivery, but not term delivery [6]. Similarly, the study by Smith et al. [8] from Scotland showed a seven-fold higher risk of ischemic heart disease admission or death in women who had pre-eclampsia, delivered pre-term and whose baby was in the lowest quintile for birth weight. A Swedish cohort of 403 000 women who gave birth to their first child had similar rates of increased risk for fatal or non-fatal ischemic heart disease following pre-eclampsia, 4–14 years after the index pregnancy [9]. Together, these studies suggest that pre-eclampsia either increases future cardiovascular risk or that pre-eclampsia tends to affect women who have existing cardiovascular risk factors. Current evidence supports the latter hypothesis, namely that women who develop pre-eclampsia are more likely to have existing cardiovascular risk factors. Accordingly, the risk factors for cardiovascular disease are the same as those that are commonly found in women with pre-eclampsia, namely dyslipidemia, insulin resistance, obesity, hypertension and a family history of cardiovascular disease [3]. Furthermore, in women who have had pre-eclampsia, similar abnormalities have been demonstrated [10,11]. Endothelial dysfunction is a common clinical manifestation of the maternal pre-eclamptic syndrome, with increased capillary permeability, abnormalities of thromboxane/prostacyclin homeostasis and increased platelet aggregation being observed [3]. Endothelial dysfunction is now considered to be a hallmark of conditions associated with atherosclerosis [12]. During pre-eclamptic pregnancy, endothelial vasodilator function was reduced when assessed by Doppler measures following reactive hyperemia [13]. Using direct infusion of acetylcholine in pregnant women, Bowyer et al. [14] also showed that forearm blood flow responses were reduced; however, in this study, the pressor responses to the nitric oxide synthase inhibitor NG-monomethyl-L-arginine did not vary between normal and hypertensive pregnant women, suggesting that non-nitric oxide mechanisms may have been involved. There have been several studies examining endothelial function in women with prior pre-eclampsia. Chambers et al. [15] showed reduced flow-mediated dilatation in women with previous pre-eclampsia compared to controls. In another indirect study, Agatisa et al. [16] measured forearm blood flow responses to a mental stress test, and demonstrated impaired endothelial function in women with a history of pre-eclampsia up to 1 year post-partum [16]. In both of these studies, blood pressure was slightly higher in the women with previous pre-eclampsia. In the current issue of the journal, Lampinen et al. [17] contribute to the understanding of this pathophysiology. They examined 30 women with a history of proteinuric pre-eclampsia, who were randomly selected from a group of women with moderate to severe disease. This group was compared with 21 women with prior normal pregnancy, 5–6 years after the index pregnancy, excluding any hemodynamic effect of the pregnancy on the vascular studies. Forearm blood flow was measured by bilateral venous occlusion plethysmography. Endothelial vasodilator function was measured by the intra-arterial infusion of acetylcholine and endothelium-independent vasodilatation by the intra-arterial infusion of sodium nitroprusside. Arterial stiffness was examined by pulse-wave analysis. The groups were similar with respect to age, body mass index and cigarette smoking; however, blood pressure was higher in the previous pre-eclamptic group compared to the control group. Both endothelium-dependent and independent vasodilatation were attenuated in these previous pre-eclamptic women. However, there was no evidence of increased arterial stiffness. The authors made efforts to exclude age, body mass index and blood pressure as factors by multiple regression analysis. The study confirms the presence of abnormal vasodilatation using a reproducible and relatively robust experimental protocol in women with previous pre-eclampsia. The authors suggest that signalling pathways of vascular smooth muscle may be involved in addition to reduced nitric oxide bioavailability in view of the reduction in endothelium-independent vasodilatation. The recently described putative mechanisms involving NO/cGMP in vascular smooth muscle (in animal studies) have not been demonstrated in human hypertension. Interestingly, vascular smooth muscle calcium sensitivity was increased in vessels from pre-eclamptic women [18]. Most, but not all studies examining vasodilator function in human essential hypertension have demonstrated endothelial dysfunction, but not smooth muscle dysfunction. Hence the study by Lampinen et al. [17] raises the possibility that women at risk for future cardiovascular disease have endothelial and/or vascular smooth muscle dysfunction. However, there are limitations of the study that must be considered. First, numbers were small and co-morbidities known to affect endothelial function were not reported, including blood glucose and lipid profiles [12]. Second, hypertension is the most well described association with endothelial dysfunction [19] and, despite the statistical analysis (multiple regression) employed to exclude this as a possible confounding factor, systolic blood pressure was 11 mmHg higher in women with previous pre-eclampsia than in the control group, and the study may have been underpowered to exclude the effect of this difference in blood pressure. Further studies aiming to identify clinically relevant markers of future cardiovascular risk would be welcome in this relatively high-risk group of young women. Two possibilities generated by studies such as that conducted by Lampinen et al. [17] are: (i) has the pre-eclamptic pregnancy caused irreversible physiological change leading to increased cardiovascular risk or (ii) were the common risk factors for cardiac disease and pre-eclampsia responsible for the development of pre-eclampsia in women who had these risk factors prior to their first confinement? Only a longitudinal study examining cardiovascular risk factors, baseline blood pressure, genetic and environmental factors, vascular function and probably many other variables before, during and after pregnancy would be able to answer such a question. Whether or not the above study is ever performed may be irrelevant. In developed countries, pregnancy may be the first time that many women seek any medical attention in their adult lives. A pre-eclamptic pregnancy therefore should be considered as a positive ‘stress test’ for future cardiovascular risk in young women [20]. Clearly, there remain unmodifiable risk factors, but studies such as that by Lampinen et al. [17] tell us that, as early as 5–6 years post-partum, these women have identifiable abnormalities of vascular function categorizing them as having an increased cardiovascular risk. At this stage, at the very least, it is prudent to counsel these women on the benefits of lifestyle modifications proven to reduce or reverse the physiological or metabolic abnormalities common in this group.
No takes yet. Share an insight, caveat, or question.
George Mangos (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: